Allogene director granted 95,400 RSUs

Barrett Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Barrett Elizabeth A. reported acquisition or exercise transactions in this Form 4 filing.

Allogene Therapeutics, Inc. director Elizabeth A. Barrett received a grant of 95,400 Restricted Stock Units. Each RSU represents a contingent right to one share of Allogene common stock.

The RSUs vest in two equal semi-annual installments over one year from the grant date, subject to her continued service. Barrett has elected to defer delivery of the underlying shares until the earlier of 30 days after leaving continuous service or a change in control of the company.

Insider Trade Summary

Grant/Award: 95,400 shares

Grant/Award 1 txn

Insider Barrett Elizabeth A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit	95,400	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 95,400 contracts (Direct)

Footnotes (1)

F1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.

Key Figures

RSUs granted: 95,400 units Underlying shares: 95,400 shares Transaction price per RSU: $0.0000 per unit +3 more

6 metrics

RSUs granted 95,400 units Restricted Stock Units awarded to director on 2026-06-18

Underlying shares 95,400 shares Each RSU represents one share of common stock

Transaction price per RSU $0.0000 per unit Reported grant price for the RSU award

Total RSUs after grant 95,400 units Total RSU holdings reported following this transaction

Vesting schedule Two equal semi-annual installments Over one year from the grant date, subject to continued service

Deferral timing Earlier of 30 days after separation or change in control Timing elected for receipt of common stock upon vesting

Key Terms

Restricted Stock Units (RSUs), contingent right, Non-Employee Director Compensation Policy, change in control

4 terms

Restricted Stock Units (RSUs) financial

"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share..."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Company Common Stock."

Non-Employee Director Compensation Policy financial

"The reporting person has elected to defer the receipt of Common Stock... pursuant to the Company's Non-Employee Director Compensation Policy..."

change in control financial

"until earlier of (i) 30 days following separation from continuous service... and (ii) a change in control of the Company."

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Allogene Therapeutics (ALLO) disclose for Elizabeth A. Barrett?

Allogene Therapeutics disclosed that director Elizabeth A. Barrett received a grant of 95,400 Restricted Stock Units. These RSUs are a form of equity compensation that convert into common shares over time, aligning director incentives with shareholder interests through stock-based awards.

How many Restricted Stock Units did the Allogene (ALLO) director receive?

Elizabeth A. Barrett received 95,400 Restricted Stock Units from Allogene Therapeutics. Each RSU entitles her to one share of common stock upon settlement, subject to vesting conditions and her continued service on the company’s board during the one-year vesting period.

What is the vesting schedule for Elizabeth A. Barrett’s Allogene (ALLO) RSU grant?

The 95,400 RSUs granted to Elizabeth A. Barrett vest in two equal semi-annual installments over one year from the grant date. Vesting requires her continued service as a director through each vesting date, making the award contingent on ongoing board participation.

Did Elizabeth A. Barrett pay anything for the Allogene (ALLO) RSUs?

No cash payment is indicated for Elizabeth A. Barrett’s RSU grant; the transaction price per unit is reported as 0.0000. RSUs are typically granted as part of director compensation, rather than purchased on the open market like ordinary share acquisitions.

When will Elizabeth A. Barrett receive Allogene (ALLO) shares from her RSUs?

Barrett elected to defer receipt of Allogene common stock until the earlier of 30 days after separating from continuous service or a change in control. Shares are also subject to the RSUs vesting in two semi-annual installments during the one-year vesting period.

How many Allogene (ALLO) shares does the RSU grant represent for the director?

The RSU grant represents rights to 95,400 underlying shares of Allogene common stock, because each RSU equals one share. These shares will only be delivered if the RSUs vest and after the elected deferral conditions for settlement are satisfied under company policies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 04:26 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barrett Elizabeth A.

(Last)

(First)

(Middle)

210 EAST GRAND AVENUE

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	06/18/2026		A		95,400		⁽¹⁾	⁽¹⁾	Common Stock	95,400	$0	95,400	D

Explanation of Responses:

1. Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i) 30 days following separation from continuous service with the company and (ii) a change in control of the Company.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR